Efavirenz – a new drug for HIV infection therapy in the drug portfolio of Promomed Group

Efavirenz, the drug used in the treatment of HIV infection, received marketing authorization^* and became the fourth drug in the Promomed Group's antiretroviral portfolio. This drug product is included in the first-line antiretroviral therapy (ART) regimens for adults and children.

Antiviral activity of Efavirenz is dependent on inhibition of HIV−1 reverse transcriptase. The drug is used in combination antiviral therapy. It is indicated for use in adults and children aged 3+ years infected with the human immunodeficiency virus of type 1. Antiviral therapy is the key to the success of the treatment of patients with HIV infection; it helps to increase in life expectancy and maintain the quality of life.

The development and production of drug products for the treatment of major critical diseases, including the human immunodeficiency virus, is one of the most important strategic directions in the activities of Promomed Group, a company focused on solving significant medical problems, saving and significantly improving the quality of life of patients.

Efavirenz will be available in tablets containing 100 to 600 mg of active ingredient, which corresponds to standard dosage regimens.

Like most drug products produced by Promomed Group, Efavirenz is included in the List of vital and essential drugs (VED list).